- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Belite Bio outlines regulatory path and $275.6M cash position while preparing for Tinlarebant commercialization | 1 | Seeking Alpha | ||
| BELITE BIO Aktie jetzt für 0€ handeln | |||||
| 10.11. | Belite Bio GAAP EPS of -$0.28 beats by $0.20 | 2 | Seeking Alpha | ||
| 10.11. | Belite Bio, Inc Q3 Loss Increases | - | RTTNews | ||
| 10.11. | Belite Bio GAAP EPS of -$0.28 | 1 | Seeking Alpha | ||
| 10.11. | BELITE BIO, INC - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 04.11. | Belite Bio stellt Fortschritte bei Stargardt-Therapie vor - Top-Line-Daten aus Phase-3-Studie erwartet | 2 | Investing.com Deutsch | ||
| 02.11. | Belite Bio, Inc: Belite Bio Announces UK's Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant | 2 | GlobeNewswire (USA) | ||
| 17.10. | Belite Bio stock rating reiterated at Buy by H.C. Wainwright | 1 | Investing.com | ||
| 16.10. | Belite Bio: ADR-Aktie markiert Rekordhoch bei 86,61 USD | 3 | Investing.com Deutsch | ||
| 15.10. | Belite Bio: China NMPA Agrees To Accept NDA With Priority Review For Tinlarebant | - | RTTNews | ||
| 15.10. | Belite Bio, Inc: Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant | 170 | GlobeNewswire (Europe) | NMPA's response is based on the Phase 3 DRAGON interim analysis resultsTopline final data expected in Q4 2025 SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage... ► Artikel lesen | |
| 15.09. | Belite Bio: H.C. Wainwright senkt Kursziel auf 98 Dollar aufgrund erhöhter Aktienanzahl | 1 | Investing.com Deutsch | ||
| 12.09. | Belite Bio completes last subject visit in phase 3 Stargardt trial | 2 | Investing.com | ||
| 12.09. | Belite Bio, Inc: Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease | 311 | GlobeNewswire (Europe) | Tinlarebant has been granted Breakthrough Therapy, Fast Track, and Rare Pediatric Disease Designations in the U.S.; Orphan Drug Designation in the U.S., Europe, and Japan; and Pioneer Drug Designation... ► Artikel lesen | |
| 10.09. | Benchmark reiterates Buy rating on Belite Bio stock after $275 million PIPE | 12 | Investing.com | ||
| 08.09. | Belite Bio sichert sich 125 Millionen Dollar durch Privatplatzierung für Augenmedikamente | 2 | Investing.com Deutsch | ||
| 08.09. | Belite Bio raises $125 million in private placement for eye disease drugs | 1 | Investing.com | ||
| 08.09. | Belite Bio, Inc: Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors | 1 | GlobeNewswire (USA) | ||
| 08.09. | BELITE BIO, INC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.08. | Belite Bio auf H.C. Wainwright Konferenz: Strategischer Fokus auf Augenkrankheiten | 1 | Investing.com Deutsch |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 0,386 | +1,42 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results | Held meeting with U.S. Food and Drug Administration (FDA) where, among other things, they reiterated October 2024 agreement to use estimated glomerular filtration rate (eGFR) slope as an endpoint... ► Artikel lesen | |
| ARGENX | 786,80 | +0,74 % | Argenx Gains Health Canada Approval For Vyvgart SC As Monotherapy In CIDP | WASHINGTON (dpa-AFX) - argenx SE (ARGX), Wednesday, announced that Health Canada has issued a Notice of Compliance authorizing VYVGART SC as a monotherapy for the treatment of adult patients... ► Artikel lesen | |
| AVID BIOSERVICES | 12,100 | 0,00 % | Avid Bioservices appoints Dave Stewart as Chief Technology and Transformation Officer | The newly created role marks a major step in CEO Kenneth Bilenberg's vision to scale Avid for its next chapter of growth.
TUSTIN, Calif., Nov. 10, 2025 /PRNewswire/... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 1,630 | +1,88 % | Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results | Company to host conference call and webcast today at 8:00 a.m. EST
CARMIEL, Israel, Nov. 13, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:... ► Artikel lesen | |
| ENZO BIOCHEM | 0,388 | 0,00 % | Battery Ventures Completes Take-Private of Enzo Biochem | Apter joins as CEO to support the next stage of growth for the life-science reagents platform
BOSTON--(BUSINESS WIRE)--Battery Ventures, a global, technology-focused investment firm, announced the... ► Artikel lesen | |
| QUANTERIX | 5,745 | 0,00 % | Quanterix Corp Q3 Loss Increases, Misses Estimates | ||
| LEXEO THERAPEUTICS | 9,000 | 0,00 % | Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights | FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier co-primary endpoint assessment, to support a Biologics License Application FDA approved... ► Artikel lesen | |
| COGENT BIOSCIENCES | 33,540 | 0,00 % | Aktien New York: Gewinne dank Signalen für Shutdown-Ende | NEW YORK (dpa-AFX) - An den US-Börsen knüpfen die Kurse am Montag mit einer Erholung an die späte Kursstabilisierung vom Freitag an. Wie schon zuvor in Asien und Europa hellten Anzeichen für eine mögliche... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 40,850 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 - - Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 - - Conference call... ► Artikel lesen | |
| NUVALENT | 96,50 | 0,00 % | Nuvalent, Inc. - 8-K, Current Report | ||
| AVIDITY BIOSCIENCES | 70,80 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| INVIVYD | 2,345 | 0,00 % | Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights | PEMGARDA® (pemivibart) net product revenue of $13.1 million reported for Q3 2025, representing 41% growth year-over-year and 11% growth quarter-over-quarterOctober 2025 ending cash and cash equivalents... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,135 | 0,00 % | Change at the top of Recursion as co-founder leaves CEO role | ||
| ARCUTIS BIOTHERAPEUTICS | 25,070 | 0,00 % | Arcutis completes enrollment in infant atopic dermatitis study | ||
| KYMERA THERAPEUTICS | 64,94 | 0,00 % | Kymera Therapeutics: Stifel bekräftigt "Buy"-Rating im Vorfeld entscheidender Daten |
BELITE BIO INC ADR gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +1,00 (+1,02 %) liegt der Kurs bei 99,00 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BELITE BIO INC ADR finden Sie auf Wallstreet Online.